FORMULA FOR N-13 AMMONIA
Founded in 2009 from technology born at MIT Plasma Science and Fusion Center, IONETIX is a pioneering radio-pharmaceutical end-to-end solution provider for cardiac PET imaging born out of an unmet clinical need in this space.
In the past, access to N-13 Ammonia, one of the most accurate PET imaging agents for the detection of CAD, was limited due to the location proximity needed for conventional cyclotrons.
In response to that challenge, IONETIX developed the world’s first compact superconducting cyclotron. Called the ION-12SC, the cyclotron produces N-13 Ammonia and is small enough to be installed on or near the campus of PET programs. IONETIX covers all costs related to the installation and ongoing operation of the cyclotron. N-13 Ammonia can be ordered on demand through a pay-by-the-dose model, making the tracer both accessible and affordable to providers across the country.
IONETIX Corporation is committed to the design, manufacturing, and support of safe and effective radiopharmaceutical products which meet or exceed the expectations of customers, medical professionals, users, and applicable regulations and standards.
CHIEF EXECUTIVE OFFICER
Prior to joining Ionetix in 2011, Mr. Cameron served as President of Glass, Lewis & Co., a leading independent corporate governance research firm which he co-founded in 2003. Prior to Glass Lewis, he served as General Counsel at Moxi Digital, a technology venture founded by Microsoft co-founder Paul Allen. Mr. Cameron previously served as General Counsel at NorthPoint Communications, a publicly-traded broadband telecommunications company acquired by AT&T. Before NorthPoint, he was an attorney with the corporate law firm of Kellogg, Huber, Hansen, Todd & Evans in Washington D.C. and served as a law clerk to the Hon. James L. Buckley of the United States Court of Appeals for the District of Columbia Circuit. Mr. Cameron is a director of KERYX Biopharmaceuticals (NASD:KERX), a director of AvidBiotics, a former director of Reddy Ice, and was a founding board member of ProCure Treatment Centers, the leading provider of proton therapy treatment in the U.S. He earned a J.D. from the University of Chicago and a B.A. at McGill University.
CHIEF OPERATIONS OFFICER
Prior to joining Ionetix in 2017, Mr. Stagnolia served as COO for Zevacor Pharma (formerly IBA Molecular NA), a leader in radiopharmaceutical manufacturing and distribution. Prior to joining IBA Molecular NA, he served as COO for PETNET Solutions, A Siemens Company. PETNET Solutions operates the largest network of PET radiopharmacies with a global network of integrated manufacturing operations and PET nuclear pharmacies. Prior to joining PETNET Solutions, Mr. Stagnolia held multiple manufacturing and operational leadership positions at International Paper Company. He earned his B.S. in Chemical Engineering from the University of Tennessee and M.B.A from the University of Memphis.
CHIEF FINANCIAL OFFICER
Prior to joining Ionetix in 2019, Ms. Hargreaves served as VP Business Intelligence at Invuity Inc., a publicly traded medical device company focused on providing surgeons with improved direct visualization in minimally invasive surgeries. Prior to Invuity, Ms. Hargreaves led the accounting and finance department at Hint Inc, a consumer beverage company distributed widely across the US. Before Hint Inc. Ms. Hargreaves worked in London as Finance Director for Dove Spa, a Unilever Ventures backed company, focused on premium, professional skincare and treatments. Her early career was spent in investment banking, at JP Morgan and Robert Fleming & Co. primarily involved in leveraged and acquisition finance. She earned her B.A.(Hons) in Chemistry at Oxford University.
VP, ENGINEERING & NEW PRODUCT DEVELOPMENT
Prior to joining Ionetix in 2012, Dr. Vincent served as the Chief Engineer and Electronics Department Head at the National Superconducting Cyclotron Laboratory at Michigan State University. He previously held the position of RF Project Leader at NSCL. Dr. Vincent is a veteran of the United States Army. He earned his Ph.D., M.S. and B.S. in Electrical Engineering from Michigan State University.
VP, MEDICAL AFFAIRS
Prior to joining Ionetix in 2013, Mr. Eve served as Vice President of Operations and Strategic Development at Soteria Imaging Services, LLC, a national leader in outpatient medical imaging. He previously served as Vice President of Technical Services, Vice President of PET Operations and Director of Facility Operations. Mr. Eve earned his B.S. in Nuclear Medicine from Wheeling Jesuit University.
VP, SALES & MARKETING
Prior to joining Ionetix in 2020, Mr. Burke served as Vice President of Sales Marketing for SOFIE (formerly IBA Molecular NA), a leader in commercial radiopharmaceutical manufacturing and research. From 2000 to 2012 Mr. Burke was a leader at Cardinal Health Nuclear Pharmacy services, (formerly Syncor), holding numerous Sales, Marketing and Operational roles. Peter is a graduate of the Ohio State University.
We are expanding our Finance Department by seeking an Accountant to work in Lansing, MI.
In this role, you will have the opportunity to build out the accounting function as the company continues to grow. This new position will perform a broad range of accounting functions to support our domestic and international expansion.
The Accountant has responsibility for, but not limited to:
Ideal Candidates will possess:
This position receives a competitive wage, an excellent benefits package including medical, dental, vision, life insurance, 401(k) and match, stock options, and generous paid time off.
At Ionetix, we enable healthcare providers to deliver highly accurate cardiac PET imaging, offering the highest quality of diagnostic capability for nuclear imaging services, to implement and improve cardiac PET programs.
Ionetix is an Equal Opportunity Employer